Sector: Health Care
Director information for PACIRA BIOSCIENCES INC (data for year 2025)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Abraham Ceesay | Chief Executive Officer, Rapport Therapeutics, Inc. | 47 | ["Business Development / M&A", "Human Capital Management", "Industry Experience", "Operations, Manufacturing & Supply Chain", "Research & Development"] | ["Audit", "People & Compensation"] | 2025 |
| Alethia Young | Chief Financial Officer, Bicycle Therapeutics, Inc.; Independent Director | 46 | ["25 years of financial expertise in the healthcare and biopharmaceutical industry", "Corporate finance leader providing oversight in financial reporting, internal controls, risk management and regulatory compliance", "Expertise in biopharma industry through leading equity research teams", "Insights into market and industry trends", "Senior financial leadership experience in investor relations, corporate communications and corporate strategy", "Proven track record of raising capital as CFO of Bicycle Therapeutics", "Experience in corporate restructurings"] | ["Audit"] | 2025 |
| Brendan Teehan | Chief Commercial Officer | 56 | ["Accomplished biopharmaceutical executive with over 30 years of successful commercial leadership", "Expertise in sales, marketing and portfolio strategy for commercialized non-opioid products", "Extensive leadership experience in both privately and publicly held companies across multiple large and rare disease therapeutic categories and development stages", "Oversaw a public biopharmaceutical company\u2019s first rare disease asset launch and division\u2019s international commercial build and expansion"] | [] | 2025 |
| Christopher Christie | Managing Member, Christie Solutions, LLC; and former Governor of the State of New Jersey; Independent Director | 62 | ["Government, Public Policy & Regulatory Affairs", "Human Capital Management", "Industry Experience", "Senior Leadership", "Extensive expertise in regulatory affairs, public policy and government relations", "Public thought leader on combating the opioid crisis", "Expertise in public health policy", "Public policy consultant"] | ["Nominating, Governance and Sustainability"] | 2025 |
| Frank D. Lee | Chief Executive Officer, Pacira BioSciences, Inc.; Chief Executive Officer and Director | 57 | ["Nearly three decades of global experience", "Strong track record of product development and commercial success", "Focus on patient outcomes", "Driving revenue growth and success in scaling blockbuster therapies", "Transformed organization from an early-stage drug discovery company into a clinical development company", "Global development and commercialization strategy", "U.S. P&L responsibility for major pharmaceutical products", "Responsible for setting the strategic direction of the Company", "Day-to-day leadership and management of the Company", "Provides input to the independent chair of the board for board meetings and other matters", "Facilitates communication between management and the board", "Nearly three decades of global experience in product development and commercial success", "Transformed Forma Therapeutics into a company focused on clinical development", "Responsible for driving global development and commercialization strategy at Genentech", "Formerly responsible for U.S. P&L for Herceptin\u00ae, Perjeta\u00ae, and Kadcyla\u00ae"] | ["Audit"] | 2025 |
| JONATHAN SLONIN, M.D. | Chief Medical Officer | 50 | ["Chief Medical Officer overseeing research and development and customer-facing medical operations", "Over 15 years of senior experience in clinical leadership and medical strategy", "Board-certified anesthesiologist", "Held several medical leadership positions", "Demonstrated ability to lead clinical teams, optimize medical practices, and drive operational excellence"] | [] | 2025 |
| KRISTEN WILLIAMS, ESQ. | Chief Administrative Officer and Secretary | 51 | ["Extensive experience in corporate law, including complexities surrounding public and private M&A, corporate finance, securities law and compliance.", "Deep experience with healthcare industry acquired through a prior corporate role and her law practice with a core focus in healthcare."] | [] | 2025 |
| Laura Brege | Senior Advisor to BridgeBio Pharma, Inc.; and former Chief Executive Officer, Nodality, Inc.; Independent Board Chair; Independent Director | 67 | ["Over 35 years of leadership in pharmaceutical, biotechnology and venture capital", "Contributes to the board\u2019s oversight of strategic growth initiatives and capital allocation strategies", "Corporate governance experience gained through service on public company boards", "Proven track record in leading corporate functions and teams responsible for commercialization of drugs and treatments", "Brings substantial insights into business development and growth strategies", "CFO of COR Therapeutics, oversaw rapid growth to commercially launching a successful cardiovascular drug treatment"] | ["Audit", "People & Compensation", "Nominating, Governance & Sustainability", "Nominating", "Governance and Sustainability", "Nominating, Governance and Sustainability Committee"] | 2025 |
| Marcelo Bigal, MD, PhD | President and Chief Executive Officer, Ventus Therapeutics, Inc. | 55 | [] | [] | 2025 |
| MARCELO BIGAL, M.D., Ph.D. | Independent Director | 55 | ["Leader in the pharmaceutical R&D space", "Over 20 years of medical affairs expertise", "Senior leader at several public and private biotechnology companies", "Proven commercialization oversight of globally-reaching pain management medicines", "Established track record of R&D program success", "Published over 330 peer-reviewed papers", "Recognized by the American Academy of Neurology with the Harold G. Wolff Award"] | ["Science and Technology"] | 2025 |
| Mark I. Froimson, MD | Principal, Riverside Health Advisors | 64 | [] | ["Audit"] | 2025 |
| MARK I. FROIMSON, M.D. | Independent DIRECTOR | 64 | ["Over 30 years of leadership experience in the healthcare industry", "Medical staff surgeon for the Cleveland Clinic Hospital", "CEO of Lazurite", "Chief Clinical Officer of Trinity Health", "Executive and medical leadership, advocacy and public policy expertise"] | ["Audit", "Science & Technology"] | 2025 |
| Mark Kronenfeld, M.D. | Independent Director | 70 | ["Extensive experience in clinical, business and healthcare leadership", "Management and leadership experience including perioperative care, patient safety, efficiency and financial results", "Healthcare sector investment experience with emphasis on innovation and commercial success", "Understanding of interdependence in healthcare industry including medical research, patient care, regulatory compliance", "Consultant and investor in healthcare, biomedical and medical technology", "Contributed to transformation and growth of Hackensack University Medical Center"] | ["Nominating, Governance and Sustainability, Chair", "Science & Technology", "People & Compensation"] | 2025 |
| Mark Kronenfeld, MD | Chairman of Anesthesiology, Maimonides Medical Center | 70 | [] | ["Audit"] | 2025 |
| Michael Yang | Strategic Advisor to early-stage biotech companies and Former Chief Executive Officer, ViaCyte, Inc.; Independent Director | 63 | ["Over 25 years of pharmaceutical and biotechnology leadership experience", "Proven track record of strategic execution in pharmaceutical, medical device, and diagnostic markets", "As Chief Commercial Officer for a global biotechnology company, responsible for guiding the development and scaling of its U.S. immunology business", "Launched innovative platforms, expanding global revenues and diversifying product lines", "Oversaw numerous successful drugs, including the commercialization of NUPLAZID at Acadia Pharmaceuticals"] | ["Audit", "People & Compensation"] | 2025 |
